won't be long before next major announcement, page-21

lu888
The contents of your FDA article are not set in stone. Dendreon has more or less just completed their phase3 trial with 500 participants. Dendreon have not started a iv trial and their drug most likely will be approved in the next 6 months. Their drug is designed for prostate cancer in which there are 200000 new cases diagnosed in the US each year. There are less than 30000 new cases of ovarian cancer diagnosed in the US each year,big difference.Dendreon has cut a path to commercialisation which Prima can now use to its advantage.

Dig a little deeper with your research.Cheers